OVARIAN CANCER and US: vaccine clinical trial

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label vaccine clinical trial. Show all posts
Showing posts with label vaccine clinical trial. Show all posts

Sunday, February 19, 2012

not yet recruiting: A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 - Full Text View - ClinicalTrials.gov



A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901
This study is not yet open for participant recruitment.
Verified February 2012 by Duke University

First Received on January 24, 2012. Last Updated on February 1, 2012 History of Changes
Sponsor: Duke University
Collaborator: Department of Defense
Information provided by (Responsible Party): Duke University
ClinicalTrials.gov Identifier: NCT01526473
Purpose
HER2 is a protein that is over expressed in 20-30% of breast cancers. It is also found associated with lung, gastric, ovarian, and pancreatic cancers. Although there are existing therapies that can target HER2, most patients will eventually experience progression of their disease even though their cancer continues to express HER2. Therefore, new approaches are needed for treating tumors that express HER2.
This clinical trial will use an investigational cancer vaccine called HER2 VRP or AVX901. The vaccine is based on a virus called Venezuelan equine encephalitis but it has been changed so it cannot cause active infection. Instead, the virus has been changed so it tells the immune system to attack cancer cells which make HER2.
The objectives of the study are to evaluate the safety of immunization with HER2 VRP in patients with advanced or metastatic malignancies that express HER2, and to test whether immunization will causes a strong immune system attack against the cancer.

Condition Intervention Phase
HER2+ Cancer Biological: AVX901 Phase I

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Phase I Study To Evaluate The Antitumor Activity And Safety Of DUKE-002-VRP(HUHER2-ECD+TM), An Alphaviral Vector Encoding The HER2 Extracellular Domain And Transmembrane Region, In Patient With Locally Advanced Or Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Cancers Including Breast Cancer